Evidence map›Paper›PMID 34363843›Full record

ArticleNeurotoxicology2021

Effects of route of administration on neural exposure to platinum-based chemotherapy treatment: a pharmacokinetic study in rat.

Stephen N Housley, Travis M Rotterman, Paul Nardelli, Dario I Carrasco, Richard K Noel, Laura O'Farrell, Timothy C Cope

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neurotoxicology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 87% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Stephen N HousleySchool of Biological Sciences, Georgia Institute of Technology, Atlanta, 30332, Georgia; Integrated Cancer Research Center, Parker H. Petit Institute for Bioengineering and Bioscience, Georgia Institute of Technology, 315 Ferst Drive, Atlanta, GA, 30309, USA. Electronic address: nickhousley@gatech.edu.
Travis M RottermanSchool of Biological Sciences, Georgia Institute of Technology, Atlanta, 30332, Georgia.
Paul NardelliSchool of Biological Sciences, Georgia Institute of Technology, Atlanta, 30332, Georgia.
Dario I CarrascoSchool of Biological Sciences, Georgia Institute of Technology, Atlanta, 30332, Georgia.
Richard K NoelPhysiological Research Laboratory, Georgia Institute of Technology, Atlanta, GA, USA.
Laura O'FarrellPhysiological Research Laboratory, Georgia Institute of Technology, Atlanta, GA, USA.
Timothy C CopeSchool of Biological Sciences, Georgia Institute of Technology, Atlanta, 30332, Georgia; Integrated Cancer Research Center, Parker H. Petit Institute for Bioengineering and Bioscience, Georgia Institute of Technology, 315 Ferst Drive, Atlanta, GA, 30309, USA; W.H. Coulter Department of Biomedical Engineering, Emory University and Georgia Institute of Technology, Georgia Institute of Technology, Atlanta, 30332, Georgia. Electronic address: tim.cope@gatech.edu.
Georgia Institute of Technology · US

Funding

Novel Path to Chronic Sensorimotor Dysfunction and Treatment for ChemotherapyR01CA221363 · NCI · GEORGIA INSTITUTE OF TECHNOLOGY · PI COPE, TIMOTHY C · 2018 to 2022
$1.5M
NCI NIH HHS R01 CA221363
6 · The paper itself

Abstract

The persisting need for effective clinical treatment of chemotherapy-induced neurotoxicity (CIN) motivates critical evaluation of preclinical models of CIN for their translational relevance. The present study aimed to provide the first quantitative evaluation of neural tissue exposed in vivo to a platinum-based anticancer compound, oxaliplatin (OX) during and after two commonly used dosing regimens: slow IV infusion used clinically and bolus IP injection used preclinically. Inductively-coupled plasma mass spectrometry analysis of dorsal root ganglia indicated that while differences in the temporal dynamics of platinum distribution exist, key drivers of neurotoxicity, e.g. peak concentrations and exposure, were not different across the two routes of administration. We conclude that the IP route of OX administration achieves clinically relevant pharmacokinetic exposure of neural tissues in a rodent model of CIN.

Indexed as

Administration, IntravenousAnimalsAntineoplastic AgentsDrug Administration RoutesGanglia, SpinalInfusions, ParenteralOxaliplatinPlatinum CompoundsRatsRats, Inbred F344Antineoplastic AgentsOxaliplatinPlatinum CompoundsChemotherapy-induced neurotoxicityDorsal root gangliaMassspectrometryOxaliplatinPreclinical validation

Identifiers

PMID34363843
PMCPMC9175304
OpenAlexW3189817359

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.